$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Zoetis posts strong Q2 with margin expansion and raised guidance, but Librela weakness and cautious market sentiment temper near-term outlook.

# Zoetis Delivers Margin Expansion and Raises Guidance in Q2 FY2025, but Librela Weakness and Cautious Market Sentiment Linger

---

## Executive Summary

- **Zoetis (ZTS) reported Q2 FY2025 revenue of $2.46B (up 4% YoY, 8% organic growth) and adjusted EPS of $1.76, both meeting or slightly exceeding consensus expectations.** Growth was driven by strong U.S. companion animal sales (+9% YoY) and robust international performance, with volume gains outpacing price effects.
- **Margin expansion was a standout,** with U.S. gross margins reaching 84.7% and international margins at 70.7%. Operating margin improved to approximately 36.7%, reflecting effective cost control and operational leverage.
- **Management maintained a bullish tone,** highlighting innovation, broad-based growth, and disciplined cost management. The company raised its full-year revenue guidance to $9.45–$9.60B and adjusted EPS to $6.30–$6.40, citing strong H1 execution.
- **Risks remain,** particularly around the underperformance of Librela (a key osteoarthritis pain product), which saw a 7% global operational decline and a 16% drop in U.S. sales. Bearish options activity and a recent analyst downgrade suggest near-term market caution.
- **Catalyst watch:** Investors should monitor adoption trends for Librela and continued growth in alternative channels, which now represent 22% of U.S. companion animal sales and are growing at 25–30% annually.

---

## Performance Snapshot

| Metric                | Reported | Consensus | Surprise | YoY Change |
|-----------------------|----------|-----------|----------|------------|
| Revenue               | $2.46B   | ~$2.45B   | +$10M    | +4%        |
| Adjusted EPS          | $1.76    | $1.74     | +$0.02   | +~3%       |
| GAAP EPS              | $1.61    | $1.60     | +$0.01   | +~2%       |
| U.S. Companion Animal | +9% YoY  | —         | —        | +9%        |
| Alternative Channels  | +25–30%  | —         | —        | +25–30%    |
| Librela Global Sales  | -7% YoY  | —         | —        | -7%        |

---

## Earnings Quality

Zoetis delivered **high-quality earnings** this quarter, with growth driven by **organic volume increases** rather than price or one-off items. The revenue mix remains favorable, with companion animal products and international markets both contributing meaningfully. **Gross margin expansion** (U.S. 84.7%, International 70.7%) and a reduction in adjusted cost of sales (from 28.3% to 26.3% of revenue) underscore effective cost management. Operating margin improvement to 36.7% highlights the company’s ability to translate top-line growth into bottom-line gains. There is no evidence of aggressive accounting or unsustainable cost cuts.

---

## Management Commentary & Guidance

Management’s tone was **confident and optimistic**, emphasizing innovation, broad-based growth, and operational discipline. The company **raised full-year guidance** to $9.45–$9.60B in revenue and $6.30–$6.40 in adjusted EPS, reflecting confidence in continued execution. Management acknowledged challenges in the Librela franchise, particularly in the U.S., but reiterated their commitment to addressing adoption and safety concerns. The outlook assumes continued strength in alternative channels and international markets, with cost discipline remaining a core focus.

---

## Key Risks

- **Product-Specific Risk:** Librela’s underperformance (7% global, 16% U.S. decline) poses a risk to the OA pain segment and could signal broader adoption or safety issues.
- **Market Sentiment:** Bearish options activity and a recent analyst downgrade may pressure the stock in the near term, despite strong fundamentals.
- **Cost Pressures:** While cost control has been strong, inflation in labor or logistics could re-emerge as a headwind.
- **Regulatory/Adoption Risks:** Ongoing concerns about product safety or regulatory changes could impact future growth, especially in key franchises.

---

## Expected Market Reaction

Despite **strong earnings and raised guidance**, the market may react cautiously in the short term due to negative sentiment from options activity and analyst downgrades. Some investors may focus on Librela’s weakness and the potential for near-term volatility. However, if Zoetis continues to deliver on margin expansion and alternative channel growth, a rebound is likely as fundamentals reassert themselves.

---

## Final Takeaway

**Zoetis delivered a strong quarter, marked by margin expansion, disciplined cost control, and raised guidance.** While the market may be overemphasizing near-term risks—particularly around Librela and sentiment-driven volatility—the underlying business remains robust. **Investors should watch for:**
1. **Librela adoption trends and management’s response to product challenges**
2. **Sustained growth in alternative channels and international markets**

The next major catalyst will be the Q3 FY2025 earnings report and any interim updates on Librela’s performance or regulatory developments. Overall, Zoetis appears well-positioned for continued growth, with the market potentially underappreciating its operational momentum and structural opportunities.

Zoetis (ZTS): Margin Gains Offset Librela Concerns

Zoetis (ZTS) is poised for continued margin expansion and resilient demand in Q2, but investors should monitor inventory and supply chain risks that could pressure near-term profitability.

# Zoetis Inc. (ZTS): Navigating Margin Expansion and Demand Resilience Ahead of Q2 Earnings

## Executive Summary: Cautious Optimism with Margin Upside Potential

We maintain a **Bullish** outlook for Zoetis Inc. (ZTS) heading into the upcoming quarter, underpinned by **robust companion animal segment growth (+7% organic in Q1 2025)** and **incremental margin improvement** from ongoing pricing and efficiency initiatives. Management’s recent upward revision of full-year guidance—**revenue to $9.425B–$9.575B and EPS to $6.20–$6.30**—signals confidence in near-term execution. However, the market may be underestimating the **potential for short-term margin headwinds** stemming from supply chain and inventory adjustments, as flagged in recent filings. Investors should closely monitor these operational nuances, as they could transiently impact Q2 profitability despite the strong top-line trajectory.

## Recent Trends Signal What’s Next: Revenue and Margin Trajectory

Zoetis delivered **Q1 2025 revenue of $2.22B** with a **gross margin of 72%**, reflecting sustained demand in the companion animal segment and effective cost management. Over the past four quarters, revenue has grown steadily, while gross and operating margins have shown incremental improvement, driven by pricing actions and operational discipline.

### Revenue, Margin, and EPS Trends (Last 4 Quarters)

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------|
| Q2 2024      | 2.18         | 71.0             | 35.8                 | 1.30    |
| Q3 2024      | 2.20         | 71.5             | 36.0                 | 1.32    |
| Q4 2024      | 2.21         | 71.8             | 36.2                 | 1.34    |
| Q1 2025      | 2.22         | 72.0             | 36.5                 | 1.36    |

**Trend:** Revenue and margins have shown consistent, incremental growth, with Q1 2025 marking the highest gross and operating margins in the past year. This momentum is expected to continue into Q2, supported by favorable product mix and cost controls.

## Management’s Forward Tone and Positioning: Confidence with Cautious Watchfulness

Management’s Q1 2025 commentary was notably constructive, emphasizing resilience and operational strength. Key statements include:  
- **“We are well positioned to deliver on our full-year commitments.”**  
- **“We continue to see steady demand in our companion animal portfolio.”**  
- **“We are navigating a fluid environment, particularly in supply chain and FX.”**

Compared to prior quarters, the tone has shifted from cautious optimism to measured confidence, with a clear focus on execution and risk management. The explicit upward revision of full-year guidance marks a more assertive stance, while ongoing references to supply chain and FX volatility indicate continued vigilance.

## KPI Trends & Upcoming Quarter Drivers: Companion Animal Growth and Efficiency

The most relevant KPIs for Q2 are **companion animal segment growth, capex, and inventory levels**.

### Key KPI Movements

| KPI                        | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|----------------------------|---------|---------|---------|------------|------------|
| Companion Animal Growth (%)| +6.5    | +6.8    | +7.0    | +0.5       | +0.2       |
| Capex ($M)                 | 140     | 145     | 149     | +6.4       | +2.8       |
| Inventory ($M)             | 1,050   | 1,080   | 1,110   | +5.7       | +2.8       |

- **Companion Animal Growth:** Sustained acceleration (+7.0% YoY in Q1 2025) is expected to drive Q2 revenue and margin expansion, especially from flagship products like Simparica Trio and Apoquel.
- **Capex:** Modest increases (+6.4% YoY) reflect ongoing investment in production capacity, supporting future growth and potential cost efficiencies.
- **Inventory:** Slight build (+5.7% YoY) suggests proactive management of supply chain risk, but also introduces potential for short-term margin pressure if not matched by demand.

## Missed by the Street: Inventory and Supply Chain Nuances

A close reading of Q1 filings and management commentary reveals **subtle but important operational shifts**:
- **“Inventory increased modestly due to higher inventory charges and supply chain considerations.”** (Q1 2025 10-Q)
- This signals that Zoetis is absorbing higher working capital costs to buffer against supply chain volatility—a risk that could pressure margins if demand softens or costs escalate further. The Street appears to be underappreciating this near-term headwind, focusing instead on headline growth.

## Scenarios for the Upcoming Quarter: Bull, Base, and Bear Cases

### Scenario Table: Q2 2025 Outcomes

| Scenario | Revenue ($B) | EPS ($) | Gross Margin (%) | Key Assumptions                                              |
|----------|--------------|---------|------------------|--------------------------------------------------------------|
| Bull     | 2.29         | 1.50    | 73.5             | Strong companion animal demand, stable FX, supply chain normalizes |
| Base     | 2.25         | 1.43    | 72.5             | Moderate growth, some FX/tariff pressure, operational execution |
| Bear     | 2.20         | 1.36    | 71.0             | FX/tariff headwinds persist, slower new product uptake, margin pressure |

**Most Likely Scenario:** The **Base case** is most probable, given current evidence of steady demand, incremental margin gains, and manageable (but not eliminated) external risks. Upside exists if supply chain and FX volatility abate, but inventory and cost signals warrant caution.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q2 2024      | 2.18         | 1.30    | 71.0             | 35.8                 |
| Q3 2024      | 2.20         | 1.32    | 71.5             | 36.0                 |
| Q4 2024      | 2.21         | 1.34    | 71.8             | 36.2                 |
| Q1 2025      | 2.22         | 1.36    | 72.0             | 36.5                 |

### KPI Movement Table

| KPI                        | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|----------------------------|---------|---------|---------|------------|------------|
| Companion Animal Growth (%)| +6.5    | +6.8    | +7.0    | +0.5       | +0.2       |
| Capex ($M)                 | 140     | 145     | 149     | +6.4       | +2.8       |
| Inventory ($M)             | 1,050   | 1,080   | 1,110   | +5.7       | +2.8       |

### Key Management Quotes and Interpretations

1. **“We are well positioned to deliver on our full-year commitments.”**  
   - *Q1 2025 Earnings Call*  
   - Indicates management confidence in meeting or exceeding guidance.

2. **“We continue to see steady demand in our companion animal portfolio.”**  
   - *Q1 2025 Earnings Call*  
   - Suggests ongoing top-line strength in the highest-margin segment.

3. **“Inventory increased modestly due to higher inventory charges and supply chain considerations.”**  
   - *Q1 2025 10-Q*  
   - Flags potential for near-term margin pressure if inventory build is not matched by sales.

4. **“We are navigating a fluid environment, particularly in supply chain and FX.”**  
   - *Q1 2025 Earnings Call*  
   - Implies ongoing external risk management is a priority.

5. **“We have raised our full-year 2025 guidance for both revenue and EPS.”**  
   - *Q1 2025 Earnings Call*  
   - Signals upward revision in management’s outlook, supporting a bullish stance.

6. **“Operational efficiency initiatives are beginning to yield incremental margin improvement.”**  
   - *Q1 2025 Earnings Call*  
   - Points to cost discipline as a lever for earnings upside.

7. **“We expect working capital to normalize in the second half of the year.”**  
   - *Q1 2025 10-Q*  
   - Suggests that current margin headwinds from working capital are likely transitory.

---

**Bottom Line:** Zoetis enters Q2 2025 with strong demand momentum and margin tailwinds, but investors should monitor inventory and supply chain signals for any signs of near-term cost pressure. The risk/reward skews positive, with the base case scenario most likely, but vigilance is warranted on operational execution.

Zoetis (ZTS): Margin Upside Amid Supply Chain Risks